3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
258
Carcinoma, Non-Small-Cell Lung
226
Carcinoma, Renal Cell
143
Neoplasm Metastasis
97
Neoplasms
93
Carcinoma, Hepatocellular
85
Squamous Cell Carcinoma of Head and Neck
84
Colorectal Neoplasms
81
Lung Neoplasms
73
Stomach Neoplasms
56
Pancreatic Neoplasms
56
Carcinoma, Transitional Cell
49
Hodgkin Disease
47
Urinary Bladder Neoplasms
42
Breast Neoplasms
40
Ovarian Neoplasms
37
Head and Neck Neoplasms
37
Triple Negative Breast Neoplasms
34
Small Cell Lung Carcinoma
33
Sarcoma
32
Prostatic Neoplasms
32
Glioblastoma
32
Brain Neoplasms
32
Recurrence
27
Kidney Neoplasms
27
Multiple Myeloma
25
Uveal Melanoma
23
Esophageal Neoplasms
23
Uterine Cervical Neoplasms
22
Skin Neoplasms
22
Interventions
Gemcitabine
13
Albumin-Bound Paclitaxel
8
Taxes
6
130-nm albumin-bound paclitaxel
6
Fluorouracil
5
Oxaliplatin
4
dehydroftorafur
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Leucovorin
3
Irinotecan
3
Losartan
2
Cisplatin
2
tocilizumab
1
selicrelumab
1
niraparib
1
irinotecan sucrosofate
1
indusatumab
1
folfirinox
1
durvalumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Tiragolumab
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
S 1 (combination)
1
Resistance Training
1
Radiotherapy, Image-Guided
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Adenocarcinoma
×
Nivolumab
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts